TCDD ameliorated colitis symptoms by suppressing Th17 cell differentiation, resulting in decreased IL-17 and IFN-γ expression, while NOR reduced colitis by promoting Treg differentiation and inhibiting the NLRP3 inflammasome [50,51]. Here, NLRP3 is linked to colitis.